ValuEngine upgraded shares of Rocket Pharmaceuticals (NASDAQ:RCKT) from a strong sell rating to a sell rating in a research note published on Tuesday.
Several other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Rocket Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, September 12th. BidaskClub raised shares of Rocket Pharmaceuticals from a buy rating to a strong-buy rating in a report on Friday, January 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a strong buy rating to the stock. Rocket Pharmaceuticals presently has an average rating of Hold and a consensus price target of $2.00.
Shares of Rocket Pharmaceuticals (RCKT) traded down $0.07 during mid-day trading on Tuesday, reaching $12.29. 299,235 shares of the company traded hands, compared to its average volume of 206,015. The stock has a market capitalization of $334.57 and a price-to-earnings ratio of -2.21. The company has a current ratio of 27.63, a quick ratio of 27.63 and a debt-to-equity ratio of 0.97. Rocket Pharmaceuticals has a 12 month low of $3.40 and a 12 month high of $15.20.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.